Vaxcyte, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vaxcyte, Inc. on July 13, 2026, regarding corporate governance changes effective July 16, 2026. The filing addresses the departure of a director and the appointment of a new director to the Board.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Director Departure: Heath Lukatch notified the Board of his retirement, effective July 16, 2026. The departure was not the result of any disagreement with the Company.
- Director Appointment: John Markels was appointed as a Class II director, effective July 16, 2026. His term expires at the 2028 annual meeting.
- Committee Assignments: Dr. Markels was appointed to the Audit Committee and Compensation Committee.
- Independence: The Board determined Dr. Markels qualifies as an independent director under Nasdaq Rules.
Guidance, Outlook, and Compensation
The filing contains no guidance, outlook, or management commentary regarding business operations or risks. Regarding compensation, Dr. Markels will be paid under the Company's standard non-employee director program. The annual equity grant value for all directors is currently set at $430,000. The Company has also entered into a standard indemnification agreement with Dr. Markels.
Key Facts for Investor Verification
- Verify the effective date of the Board composition change (July 16, 2026).
- Confirm Dr. Markels' qualifications and independence status as disclosed.
- Review the Definitive Proxy Statement on Schedule 14A (filed April 23, 2026) for full details on the Director Compensation Program.
- Note that no financial data or operational updates are included in this specific filing.